(Q37271831)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18798103%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

review article

1 reference

title

GM-CSF plus rituximab immunotherapy: translation of biologic mechanisms into therapy for indolent B-cell lymphomas (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18798103%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

1 reference

1 reference

Parameswaran Venugopal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18798103%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

author name string

Stephen J Schuster

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18798103%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

Julie C Kern

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18798103%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

Peter McLaughlin

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18798103%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

publication date

1 September 2008

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18798103%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18798103%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

volume

49

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18798103%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

issue

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18798103%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

page(s)

1681-1692

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18798103%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

cites work

Cancer statistics, 2008

1 reference

https://api.crossref.org/works/10.1080%2F10428190802216731

The World Health Organization classification of hematological malignancies report of the Clinical Advisory Committee Meeting, Airlie House, Virginia, November 1997.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802216731

The clinical course of follicular lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802216731

Follicular lymphoma international prognostic index.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802216731

New treatment options have changed the survival of patients with follicular lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802216731

From the bench to the bedside: ways to improve rituximab efficacy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802216731

Rituximab-induced inhibition of antiapoptotic cell survival pathways: implications in chemo/immunoresistance, rituximab unresponsiveness, prognostic and novel therapeutic interventions

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802216731

Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802216731

The mechanisms of action of rituximab in the elimination of tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802216731

Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802216731

Rituximab: mechanism of action and resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802216731

Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802216731

Clustered CD20 induced apoptosis: src-family kinase, the proximal regulator of tyrosine phosphorylation, calcium influx, and caspase 3-dependent apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802216731

Cross-priming of cytotoxic T cells promoted by apoptosis-inducing tumor cell reactive antibodies?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802216731

IDEC-C2B8 (Rituximab) anti-CD20 antibody treatment in relapsed advanced-stage follicular lymphomas: results of a phase-II study of the German Low-Grade Lymphoma Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802216731

Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802216731

Rituximab therapy for patients with newly diagnosed, advanced-stage, follicular grade I non-Hodgkin's lymphoma: a phase II trial in the North Central Cancer Treatment Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802216731

Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802216731

Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP al

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802216731

CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802216731

Rituximab in combination with fludarabine chemotherapy in low-grade or follicular lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802216731

The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802216731

Differential mobilization of CD34+ cells and lymphoma cells in non-Hodgkin's lymphoma patients mobilized with different growth factors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802216731

Granulocyte-macrophage colony-stimulating factor and the immune system

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802216731

Human recombinant granulocyte-macrophage colony-stimulating factor increases cell-to-cell adhesion and surface expression of adhesion-promoting surface glycoproteins on mature granulocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802216731

Differential effect of cytokine treatment on Fc alpha receptor I- and Fc gamma receptor I-mediated tumor cytotoxicity by monocyte-derived macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802216731

Role of cytokines in the treatment of acute leukemias: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802216731

Concurrent administration of granulocyte colony-stimulating factor or granulocyte-monocyte colony-stimulating factor enhances the biological activity of rituximab in a severe combined immunodeficiency mouse lymphoma model

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802216731

Granulocyte-monocyte colony-stimulating-factor augments the interleukin-2-induced cytotoxic activity of human lymphocytes in the absence and presence of mouse or chimeric monoclonal antibodies (mAb 17-1A).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802216731

Anti-tumoral effect of GM-CSF with or without cytokines and monoclonal antibodies in solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802216731

Clinical effects of monoclonal antibody 17-1A combined with granulocyte/macrophage-colony-stimulating factor and interleukin-2 for treatment of patients with advanced colorectal carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802216731

Cytotoxic functions of blood mononuclear cells in patients with colorectal carcinoma treated with mAb 17-1A and granulocyte/macrophage-colony-stimulating factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802216731

The use of radiation as a component of breast conservation therapy in National Comprehensive Cancer Network Centers

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802216731

A new schedule of CHOP/rituximab plus granulocyte-macrophage colony-stimulating factor is an effective rescue for patients with aggressive lymphoma failing autologous stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802216731

Granulocyte- and granulocyte– macrophage-colony stimulating factors induce human endothelial cells to migrate and proliferate

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802216731

10.1080/10428190802216731

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18798103%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

1 reference